CL
Therapeutic Areas
A2A Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AO-252 | Ovarian Cancer, Endometrial Cancer, Triple-Negative Breast Cancer (TNBC) | Phase 1 |
| MLL-Menin Inhibitor (via Biomea Fusion) | Leukemias (genetically defined) & certain solid cancers | Phase 1 |
| TYK2 Pseudokinase Inhibitor | Autoimmune Disorders | Preclinical |
| YAP-TEAD Inhibitor/Degrader | Cancers with YAP overexpression | Preclinical |
| KRAS Degrader | Cancers with KRAS mutations | Preclinical |
| AO-001 | Leukemia | Research |
Leadership Team at A2A Pharma
SS
Sotirios Stergiopoulos
President & CEO, Founder
EP
Edward Painter
Chairman & CIO, Founder
SV
Sridhar Vempati
Chief Strategy Officer & Executive VP of R&D, Founder
RF
Robbin Frnka
Vice President of Clinical Operations
SC
Srikumar Chellappan
Advisory Board Member, Professor and Chair of Tumor Biology at Moffitt Cancer Center